

## Isoleucine


|                            |                                   |
|----------------------------|-----------------------------------|
| <b>Type of Posting</b>     | Revision Bulletin (POSTPONEMENT)  |
| <b>Posting Date</b>        | 29-Jul-2016                       |
| <b>Official Date</b>       | 01-Aug-2016                       |
| <b>Expert Committee</b>    | Non-Botanical Dietary Supplements |
| <b>Reason for Revision</b> | Compliance                        |

In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Non-Botanical Dietary Supplements Expert Committee has revised the Isoleucine monograph. The purpose for the revision is to postpone the revision to the *Related Compounds* section of this monograph recently published in the *First Supplement to USP 39-NF 34*, because of comments received regarding the performance of the analytical procedure and potential impurity limit compliance issues. Additionally, the previous procedure that was removed from the *Related Compounds* section has been reinstated as the official procedure.

The Isoleucine Revision Bulletin supersedes the revision of the Isoleucine monograph published in the *First Supplement to USP 39-NF 34*, which is scheduled to become official August 01, 2016. The Revision Bulletin will be incorporated in the *First Supplement to USP 40-NF 35*.

Should you have any questions, please contact Huy Dinh, Senior Scientific Liaison (301-816-8594 or [hdt@usp.org](mailto:hdt@usp.org)).

## Isoleucine



C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub> 131.17  
L-Isoleucine [73-32-5].

### DEFINITION

Isoleucine contains NLT 98.5% and NMT 101.5% of L-isoleucine (C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub>), calculated on the dried basis.

### IDENTIFICATION

- **A. INFRARED ABSORPTION** (197K)

### ASSAY

- **PROCEDURE**

**Sample:** 130 mg of Isoleucine

**Blank:** Mix 3 mL of formic acid and 50 mL of glacial acetic acid.

#### Titrimetric system

(See *Titrimetry* (541).)

**Mode:** Direct titration

**Titrant:** 0.1 N perchloric acid VS

**Endpoint detection:** Potentiometric

**Analysis:** Dissolve the *Sample* in 3 mL of formic acid and 50 mL of glacial acetic acid. Titrate with the *Titrant*. Perform the blank determination.

Calculate the percentage of L-isoleucine (C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub>) in the *Sample* taken:

$$\text{Result} = \left[ \frac{(V_S - V_B) \times N_A \times F}{W} \right] \times 100$$

*V<sub>S</sub>* = *Titrant* volume consumed by the *Sample* (mL)

*V<sub>B</sub>* = *Titrant* volume consumed by the *Blank* (mL)

*N<sub>A</sub>* = actual normality of the *Titrant* (mEq/mL)

*F* = equivalency factor, 131.2 mg/mEq

*W* = *Sample* weight (mg)

**Acceptance criteria:** 98.5%–101.5% on the dried basis

### IMPURITIES

- **RESIDUE ON IGNITION** (281): NMT 0.3%
- **CHLORIDE AND SULFATE** (221), *Chloride*  
**Standard solution:** 0.50 mL of 0.020 N hydrochloric acid  
**Sample:** 0.73 g of Isoleucine  
**Acceptance criteria:** NMT 0.05%
- **CHLORIDE AND SULFATE** (221), *Sulfate*  
**Standard solution:** 0.10 mL of 0.020 N sulfuric acid  
**Sample:** 0.33 g of Isoleucine  
**Acceptance criteria:** NMT 0.03%
- **IRON** (241): NMT 30 ppm

### Delete the following:

- **HEAVY METALS, Method I** (231): NMT 15 ppm

(Official 1-Jan-2018)

### Change to read:

- **RELATED COMPOUNDS**

■ **Buffer solution:** 0.2 M monobasic sodium phosphate. Adjust with phosphoric acid to a pH of 2.8.

■ **Mobile phase:** Acetonitrile and *Buffer solution* (2:98)

■ **System suitability solution:** 0.25 mg/mL each of USP L-Leucine RS and USP L-Isoleucine RS in *Mobile phase*

■ **Standard solution:** 0.025 mg/mL of USP L-Leucine RS in *Mobile phase*

■ **Sample solution:** 5.0 mg/mL of Isoleucine in *Mobile phase*

### Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

■ **Mode:** LC

■ **Detector:** UV 210 nm

■ **Column:** 4.6-mm × 15-cm; 3-μm packing L1

■ **Column temperature:** 40°

■ **Flow rate:** 1 mL/min

■ **Injection volume:** 20 μL

### System suitability

■ **Sample:** *System suitability solution*

[NOTE—The relative retention times for isoleucine and leucine are 0.9 and 1.0, respectively.]

### Suitability requirements

■ **Resolution:** NLT 1.5 between leucine and isoleucine  
■ **Relative standard deviation:** NMT 2.0% each for leucine and isoleucine

### Analysis

■ **Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of leucine in the portion of Isoleucine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

*r<sub>U</sub>* = peak response of leucine from the *Sample solution*

*r<sub>S</sub>* = peak response of leucine from the *Standard solution*

*C<sub>S</sub>* = concentration of USP L-Leucine RS in the *Standard solution* (mg/mL)

*C<sub>U</sub>* = concentration of Isoleucine in the *Sample solution* (mg/mL)

Calculate the percentage of any unspecified impurity in the portion of Isoleucine taken:

$$\text{Result} = (r_U/r_T) \times 100$$

*r<sub>U</sub>* = peak response of any unspecified impurity from the *Sample solution*

*r<sub>T</sub>* = sum of all the peak responses from the *Sample solution*

### Acceptance criteria

■ **Leucine:** NMT 0.5%

■ **Any unspecified impurity:** NMT 0.2%

■ **Total unspecified impurities:** NMT 1.0%

■ (Postponed until 1-August-2017) (RB 1-Aug-2016)

■ **System suitability solution:** 0.4 mg/mL each of USP L-Isoleucine RS and USP L-Valine RS in 0.1 N hydrochloric acid

■ **Standard solution:** 0.05 mg/mL of USP L-Isoleucine RS in 0.1 N hydrochloric acid. [NOTE—This solution has a concentration equivalent to 0.5% of that of the *Sample solution*.]

■ **Sample solution:** 10 mg/mL of Isoleucine in 0.1 N hydrochloric acid

### Chromatographic system

(See *Chromatography* (621), *Thin-Layer Chromatography*.)

■ **Mode:** TLC

■ **Adsorbent:** 0.25-mm layer of chromatographic silica gel mixture

■ **Application volume:** 5 μL

■ **Developing solvent system:** Butyl alcohol, glacial acetic acid, and water (3:1:1)

■ **Spray reagent:** 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)

## 2 Isoleucine

### System suitability

**Sample:** *System suitability solution*

**Suitability requirements:** The chromatogram of the *System suitability solution* exhibits two clearly separated spots.

### Analysis

**Samples:** *System suitability solution, Standard solution, and Sample solution*

After air-drying the plate, spray with *Spray reagent*, and heat between 100° and 105° for 15 min. Examine the plate under white light.

**Acceptance criteria:** Any secondary spot of the *Sample solution* is not larger or more intense than the principal spot of the *Standard solution*.

**Individual impurities:** NMT 0.5%

**Total impurities:** NMT 2.0% (RB 1-Aug-2016)

### SPECIFIC TESTS

- **OPTICAL ROTATION (781S), Procedures, Specific Rotation**  
**Sample solution:** 40 mg/mL in 6 N hydrochloric acid  
**Acceptance criteria:** +38.9° to +41.8°
- **PH (791)**  
**Sample solution:** 10 mg/mL in water  
**Acceptance criteria:** 5.5–7.0
- **LOSS ON DRYING (731)**  
**Analysis:** Dry at 105° for 3 h.  
**Acceptance criteria:** NMT 0.3%

### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

### Change to read:

- **USP REFERENCE STANDARDS (11)**  
USP L-Isoleucine RS  
▪ USP L-Leucine RS<sub>11S</sub> (USP39) (Postponed until 1-August-2017) (RB 1-Aug-2016)
- USP L-Valine RS (RB 1-Aug-2016)